Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom?
Novo Nordisk is shifting its business model, with 2026 likely to represent an inflection point.
Novo Nordisk's stock price has plummeted 70% from its 2024 peak, trading at a price-to-earnings ratio of 10x, a significant drop from its five-year average of 24x. Despite the stock's decline, the company's future appears more promising than its recent past. However, Wall Street's concerns are justified, as Novo Nordisk has fallen behind Eli Lilly in the GLP-1 weight-loss drug market.
The weight-loss drug market is vast, providing room for multiple successful competitors. Novo Nordisk's recent struggles with supply and demand may be rectified by its upcoming pill version of a GLP-1 drug, which will be part of a shift to a volume-driven model. This change, while hurting financial results presently, could prove profitable if demand remains robust.
Novo Nordisk is also actively investing in new GLP-1 drugs and has initiated a $2.2 billion stock repurchase program, indicating confidence in the company's shares. With a generous 4.6% dividend yield and a payout ratio of 33%, Novo Nordisk appears undervalued, making it an attractive option for long-term investors despite the current volatility.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
